Filing Details

Accession Number:
0001479290-23-000081
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-07-05 21:11:06
Reporting Period:
2023-06-30
Accepted Time:
2023-07-05 21:11:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479290 Revance Therapeutics Inc. RVNC Pharmaceutical Preparations (2834) 770551645
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1529196 J Mark Foley C/O Revance Therapeutics, Inc.
1222 Demonbreun Street, 20Th Floor
Nashville TN 37203
Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-06-30 1,000 $15.61 892,933 No 4 A Direct
Common Stock Disposition 2023-07-03 26,279 $24.94 866,654 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 110,913 Indirect See footnote
Footnotes
  1. These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 10, 2023 by Mr. Foley.
  3. The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.73 to $25.19. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.